Conventional acne treatment presents several challenges such as intolerable side effects and antibiotic resistance. Dermocosmetic products may be used to reduce these unwanted effects. Dermocosmetics include skin cleansers, topical sebum-controllers, skin antimicrobial/anti-inflammatory agents, moisturizers, sunscreens, and camouflage products. Appropriate use of these products may help augment the benefit of acne treatment, minimize side effects, and reduce the need for topical antibiotics. In Asia, there is currently limited scientific data on the application and recommendations for dermocosmetic use in acne vulgaris (AV). This article reviews the evidence on dermocosmetics for AV and provides practice recommendations as discussed during the 4th Asia-Pacific Acne Leaders' Summit held in Bangkok, Thailand, on 7 and 8 February 2015. Through a premeeting survey, a series of plenary lectures, a stepwise program of discussion sessions, and Medline article review, the Expert Panel set forth relevant recommendations on the role of dermocosmetics as adjunct for treating AV in Asian patients.
Background
Dermatologists rely on visual findings; thus, teledermatology is uniquely compatible to providing dermatologic care. The use of mobile phones in a store-and-forward approach, where gathered data are sent to a distant health provider for later review, may be a potential bridge in seeking dermatologic care.
Objective
This study aimed to determine the agreement between face-to-face consultations and teledermatologic consultations through the store-and-forward approach using mobile phones and its accuracy compared to a histopathologic diagnosis.
Methods
The study design was a cross-sectional study of participants consecutively recruited from dermatology patients who presented with skin or mucosal complaint and without prior dermatologist consultation. Photographs were taken using a standard smartphone (iPhone 6s Plus), and a 4-mm skin punch biopsy was taken on each patient—the gold standard to which the study result was compared to. The photographs were sent to 3 consultant dermatologists using a store-and-forward approach, for independent diagnosis and treatment plan.
Results
A total of 60 patients were included, with a median age of 41 years. There was moderate-to–almost perfect agreement in terms of final diagnosis between the face-to-face dermatologic diagnosis and teledermatologic diagnoses. The third teledermatologist had the highest agreement with the clinical dermatologist in terms of final diagnosis (κ=0.84; P<.001). Among the 3 dermatologists, there was moderate-to–almost perfect agreement as well. Agreement between pairs of teledermatologists ranged from 0.45 to 0.84. The 3 teledermatologists had moderate-to-substantial agreement with the biopsy results, with the third teledermatologist having the highest accuracy (κ=0.77; P<.001). Overall, there was a moderate agreement in the diagnosis of patients across raters.
Conclusions
Teledermatology is a viable alternative to face-to-face consultations. Our results show moderate-to-substantial agreement in diagnoses from a face-to-face consultation and store-and-forward teledermatology.
Background Basal cell carcinoma (BCC) is the most common cutaneous malignancy.Multiple risk factors are associated in the development of BCC, with ultraviolet light and genetics playing major roles.Aims The departments of dermatology, medical oncology, ophthalmology, otorhinolaryngology, head and neck surgery, plastic surgery, and radiation oncology of the Jose R. Reyes Memorial Medical Center, Manila, Philippines, have convened and formulated consensus statements on the diagnosis and management of BCC patients seen in the institution.
BACKGROUND
Dermatologists rely on visual findings, thus teledermatology is uniquely compatible to provide dermatologic care. The use of mobile phones in a store-and-forward approach, where gathered data is sent to a distant health provider for later review, may be a potential bridge to seek dermatologic care.
OBJECTIVE
To determine the agreement between face-to-face consult and teledermatologic consult through the store-and-forward approach using mobile phone, and its accuracy compared to histopathologic diagnosis.
METHODS
The study design is a cross-sectional study of participants consecutively recruited from dermatology patients who presented with skin or mucosal complaint and without prior dermatologist consultation. Photographs were taken using a standard phone (iPhone 6s plus) and a 4-mm skin punch biopsy was taken on each patient, the gold standard to which the study result was compared to. The photographs were sent to three consultant dermatologists using a store-and-forward approach, for independent diagnosis and treatment plan.
RESULTS
A total of 64 patients were included, with a median age of 41 years old. There was moderate to almost perfect agreement in terms of final diagnosis between face to face dermatologic diagnosis and teledermatologic diagnoses. The third teledermatologist had the highest agreement with the clinical dermatologist in terms of final diagnosis (kappa = 0.84; p <.001). Between the three dermatologists, there was moderate to almost perfect agreement as well. Agreement between pairs of teledermatologists ranges from 0.45 to 0.84. The three teledermatologists had moderate to substantial agreement with the biopsy results, with the third teledermatologist having the highest accuracy (kappa = 0.77; p < .001). Overall, there was a moderate agreement in the diagnosis of patients across raters.
CONCLUSIONS
Teledermatology is a viable alternative to face-to-face consultations. Our results show moderate to substantial agreement in diagnoses from face-to-face consultation and store-and-forward teledermatology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.